Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-551 versus rituximab with ICE or DHAP in relapsed or refractory DLBCL
2011-002565-38Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inebilizumab in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by MedImmune. Primary endpoint: Overall response. Started Mar 2012; status: terminated.
02
Drugs
inebilizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2011-002565-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002565-38.